완전 또는 부분 반응을 달성한 중추신경계 림프종 환자 치료에 대한 유지 오비누투주맙
원발성 중추신경계 림프종 완전 또는 부분 반응자를 위한 유지 관리 오비누투주맙
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
PRIMARY OBJECTIVE:
I. To determine the effect of maintenance obinutuzumab on duration of response (partial response [PR] or complete response [CR]) in patients with CD20+ B-cell primary central nervous system lymphoma (PCNSL) who attain PR or CR to first-line treatment with high-dose methotrexate-based chemotherapy.
SECONDARY OBJECTIVES:
I. To evaluate overall survival after PR or CR (overall survival [OS]-PRCR). II. To evaluate neurocognitive function, quality of life, and neuroimaging as indicators of neurotoxicity.
III. Progression-free survival (PFS) and overall survival (OS) will be calculated.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (MAINTENANCE THERAPY): Patients receive obinutuzumab intravenously (IV) on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity.
ARM II (OBSERVATION): Patients undergo observation for a total of 2 years.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Tiffany Gervasi-Follmar
- 전화번호: 503-216-1023
- 이메일: tiffany.gervasi-follmar@providence.org
연구 연락처 백업
- 이름: Holly Marino
- 전화번호: 503-216-1034
- 이메일: holly.marino@providence.org
연구 장소
-
-
New York
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center
-
연락하다:
- Lindey Myers
- 전화번호: 917-453-2968
- 이메일: myersl1@mskcc.org
-
수석 연구원:
- Christian Grommes, MD
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- 빼는
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, 미국, 97225
- 모병
- Providence Health & Services; Providence Neurological Specialties
-
수석 연구원:
- Prakash Ambady, MD
-
연락하다:
- Kai Darke
- 전화번호: 503-216-0627
- 이메일: kai.darke@providence.org
-
연락하다:
- Kimberly Perry
- 전화번호: 971-231-8245
- 이메일: kimberly.perry2@providence.org
-
-
Pennsylvania
-
Hershey, Pennsylvania, 미국, 17033
- 모병
- Pennsylvania State University
-
수석 연구원:
- Dawit Aregawi, MD
-
연락하다:
- Micaiah Grien
- 전화번호: 283063 717-531-0003
- 이메일: mgrien@pennstatehealth.psu.edu
-
연락하다:
- Sara Craig
- 전화번호: 285799 717-531-0003
- 이메일: scraig2@pennstatehealth.psu.edu
-
-
Vermont
-
Burlington, Vermont, 미국, 05405
- 모병
- University of Vermont
-
연락하다:
- Isza Parchini
- 전화번호: 802-656-9447
- 이메일: isza.parchini@uvahealth.org
-
연락하다:
- George Davis
- 이메일: george.davis@uvmhealth.org
-
수석 연구원:
- Alissa Thomas, MD
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22903
- 모병
- University of Virginia
-
수석 연구원:
- David Schiff, MD
-
연락하다:
- Nija Desai
- 전화번호: 434-982-6455
- 이메일: NND2A@uvahealth.org
-
연락하다:
- Patrick Heffernan
- 전화번호: 434-243-9508
- 이메일: YWW2NJ@uvahealth.org
-
-
Washington
-
Seattle, Washington, 미국, 98122
- 모병
- Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute
-
연락하다:
- Nathan Hansen
- 전화번호: 206-320-3542
- 이메일: nathan.hansen@swedish.org
-
연락하다:
- Gary Brown
- 전화번호: 206-320-2608
- 이메일: gary.brown@swedish.org
-
수석 연구원:
- Alipi Bomn, MD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- CD20+ B-cell primary central nervous system lymphoma (PCNSL) confirmed at the time of diagnosis by histology, cytology, or immunocytochemistry from cerebrospinal fluid (CSF); diagnosis must be documented by pathology report.
- Must have undergone first-line treatment with a high-dose methotrexate-based chemotherapy regimen with or without brain radiotherapy; high-dose methotrexate is defined as >= 3 grams/m^2; methotrexate dose reduction for creatinine clearance < 100 ml/min is permitted
- Must be within 75 days of completion of first-line treatment regimen at the time of randomization; must have achieved objective response (PR or CR/unconfirmed complete response [CRu]) to first-line treatment
- Brain magnetic resonance imaging (MRI) documenting objective response must be obtained within 30 days before randomization
- If CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or a slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; Note: CR requires complete disappearance of all enhancing abnormalities on gadolinium-enhanced MRI; if CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; for CRu, some patients will have a small but persistent enhancing abnormality on MRI related to biopsy or focal hemorrhage; it is often difficult to ascertain whether this represents a residual nidus of tumor or scar tissue; if the abnormality does not change or slowly involutes without therapy and corticosteroids, it is reasonable to categorize as a CRu; at the time CR/CRu is determined, the patient should not have used corticosteroids for at least two weeks
- Karnofsky performance status (KPS) >= 60; Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2
- Signed informed consent form (ICF)
- Ability and willingness to comply with the requirements of the study protocol
- Total bilirubin < 3 x the upper limit of normal (ULN), ≤ 7 days before date of randomization
- Creatinine clearance > 30 mL/min (calculated according to institutional standards or using Cockcroft-Gault formula), ≤ 7 days before date of randomization
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 5 x ULN, ≤7 days before date of randomization
- Platelet ≤ 75,000 cells/mm^3, ≤ 7 days before date of randomization
- Hemoglobin > 9 g/dL, ≤ 7 days before date of randomization
- Absolute neutrophil count > 1.5 x 10^3 cells/mm^3, ≤ 7 days before date of randomization
- Surgically sterile or agree to use effective contraception using an adequate measure of contraception such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly while receiving obinutuzumab and >= 18 months after the last dose of obinutuzumab for women, and 180 days after the last dose of obinutuzumab for men
Exclusion Criteria:
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- Clinical evidence of extra-central nervous system (CNS) (systemic) non-Hodgkin lymphoma
- Known hypersensitivity to any of the study drugs
- History of other malignancy that could affect compliance with the protocol or interpretation of results
- Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are generally eligible; patients with a malignancy that has been treated, but not with curative intent, will also be excluded, unless the malignancy has been in remission without treatment for >= 2 years prior to randomization
- Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks prior to study randomization
- Major surgery within 4 weeks prior to study randomization
- Known infection with human immunodeficiency virus (HIV)
- Positive hepatitis serologies:
- Hepatitis B (HBV): patients with positive serology for hepatitis B defined as positivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc); patients who are positive for anti-HBc may be considered for inclusion in the study on a case-by-case basis if they are hepatitis B viral deoxyribonucleic acid (DNA) negative and are willing to undergo ongoing HBV DNA testing by real-time polymerase chain reaction (PCR); patients with positive serology may be referred to a hepatologist or gastroenterologist for appropriate monitoring and management
- Hepatitis C (HCV): patients with positive hepatitis C serology unless HCV ribonucleic acid (RNA) is confirmed negative and may be considered for inclusion in the study on a case-by-case basis
- Women who are pregnant or lactating
- Vaccination with a live vaccine a minimum of 4 weeks prior to study randomization
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm I (obinutuzumab
Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity. |
Given IV
다른 이름들:
Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry. Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry. |
|
활성 비교기: Arm II (observation)
Patients undergo observation for a total of 2 years. |
Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry. Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Partial response (PR) or complete response (CR) duration
기간: From the date of brain magnetic resonance imaging (MRI) after completion of first-line treatment which confirms PR or CR, to disease progression or death, assessed up to 2 years
|
PR or CR duration will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios. |
From the date of brain magnetic resonance imaging (MRI) after completion of first-line treatment which confirms PR or CR, to disease progression or death, assessed up to 2 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall survival (OS) after CR
기간: From the date of brain MRI after completion of first-line treatment which confirms PR or CR, to death, assessed up to 2 years
|
OS after PR or CR will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios. |
From the date of brain MRI after completion of first-line treatment which confirms PR or CR, to death, assessed up to 2 years
|
|
Neurocognitive function - Wechsler Adult Intelligence Scale
기간: Up to 2 years
|
Will be measured by the Wechsler Adult Intelligence Scale. Scale range 0 to 16 Forward; 0 to 14 Backward. Higher the score means better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Quality of life (QOL) - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20-item
기간: Up to 2 years
|
Will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module-20 (EORTC QLQ-BN20) questionnaire. Scale 20 to 80 points. Higher score means worse outcome. Longitudinal data of QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Progression free survival (PFS)
기간: From the start date of first-line primary central nervous system lymphoma (PCNSL) treatment to disease progression or death, assessed up to 2 years
|
PFS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
From the start date of first-line primary central nervous system lymphoma (PCNSL) treatment to disease progression or death, assessed up to 2 years
|
|
Overall survival
기간: From the start date of first-line PCNSL treatment to death, assessed up to 2 years.
|
OS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
From the start date of first-line PCNSL treatment to death, assessed up to 2 years.
|
|
Neurocognitive function - Hopkins Verbal Learning Test-Revised
기간: Up to 2 years
|
Will be measured by the Hopkins Verbal Learning Test-Revised. Test evaluates total recall, delayed recall, percent of retention, and recognition. Higher score means better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Neurocognitive function - Grooved Pegboard Test
기간: Up to 2 years
|
Will be measured by the Grooved Pegboard Test. Scale 0 seconds to time of completion in minutes and seconds. Higher time to completion means worse outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Neurocognitive function - Trail Making Test
기간: Up to 2 years
|
Will be measured by the Trail Making Test. Scale Part A: 0 seconds to 100 seconds (time of greater than 100 seconds discontinues the test. Scale Part B: 0 seconds to 300 seconds (time of greater than 300 seconds discontinues the test. Number of errors recorded. Higher time to completion and greater number of errors means worse outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Neurocognitive function - Brief Test of Attention
기간: Up to 2 years
|
Will be measured by the Trail Making Test. Scale 0 to 20 points. Higher score mean better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Quality of life (QOL) - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item
기간: Up to 2 years
|
Will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Core 30-item (EORTC QLQ-C30) questionnaire. Scale 30 to 126 points. Higher score means worse outcome. Longitudinal data of QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Prakash Ambady, MD, Providence Health & Services
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- PHS-OB-PCNSL-01
- ML29496 (기타 식별자: Genentech, Inc.)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .